CN108113980B - Application of deoxyschizandrin in inhibiting growth of multi-drug-resistant escherichia coli - Google Patents
Application of deoxyschizandrin in inhibiting growth of multi-drug-resistant escherichia coli Download PDFInfo
- Publication number
- CN108113980B CN108113980B CN201810157681.0A CN201810157681A CN108113980B CN 108113980 B CN108113980 B CN 108113980B CN 201810157681 A CN201810157681 A CN 201810157681A CN 108113980 B CN108113980 B CN 108113980B
- Authority
- CN
- China
- Prior art keywords
- escherichia coli
- drug
- deoxyschizandrin
- resistant
- resistant escherichia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention discloses an application of deoxyschizandrin in inhibiting the growth of multidrug-resistant escherichia coli, which can inhibit the growth of multidrug-resistant escherichia coli according to the fact that deoxyschizandrin has a good in-vitro killing effect on human multidrug-resistant escherichia coli such as ampicillin resistance, nalidixic acid resistance, cefotaxime resistance, ciprofloxacin resistance, cefoxitin resistance and the like, the minimum bactericidal concentration is 25.57 mu g/mL, and the minimum bacteriostatic concentration is 3.13 mu g/mL. The invention can effectively relieve or solve the problem of drug-resistant infection of the multi-drug-resistant escherichia coli, reduces the fatality rate, provides a new thought for inhibiting the human multi-drug-resistant escherichia coli, and has important practical significance.
Description
Technical Field
The invention relates to the technical field of application of effective components of traditional Chinese medicines, in particular to application of deoxyschizandrin in inhibiting growth of multi-drug-resistant escherichia coli.
Background
Currently, the world wide public health field is challenged severely. The increasing resistance of bacteria to existing antibiotics and the debilitating development of new antibiotics have made treatment of bacterial infectious diseases increasingly difficult, and humans may once again be confronted with the embarrassment of no available drugs. The generation of multiple drug-resistant bacteria brings great challenges to clinical treatment, for example, ineffective treatment not only promotes disease delay, but also consumes social resources and increases the burden of national public finance. Meanwhile, the pathogenic bacteria of drug resistance improve the incidence and mortality of infectious diseases.
The traditional Chinese medicine is used as empirical crystal for human beings struggling with diseases, plays an important role in preventing and treating bacterial infectious diseases due to rich medicinal effective components and safety and wide pharmacological action mechanism, and is always used as an important resource library for searching antibiotics to replace medicines. The Qinba mountain area has rich Chinese medicine resources, and the planting and development of Chinese herbal medicines are concerned in recent years, so that the Qinba mountain area has wide application and development prospects.
Schisandra chinensis is a plant of Schisandra (Schisandra) of Magnoliaceae, in which lignans represented by deoxyschizandrin are important active ingredients of Schisandra chinensis. Research shows that the active ingredients of the schisandra chinensis have the effects of bacteriostasis, antivirus, antioxidation, antitumor, liver protection, enzyme reduction, pain relief, immunoregulation and the like, and also have the health-care effects of warming and invigorating, tonifying qi, promoting the production of body fluid and the like.
The literature reports that the schisandra fruit extract has obvious bacteriostatic effect on escherichia coli and botrytis cinerea, and can be used for developing sterilization and anti-inflammation medicines for a digestive absorption system, food preservatives and prevention and control agents for crop botrytis cinerea. However, the bacteriostasis of the schisandra extract on human-derived multidrug-resistant escherichia coli is not reported.
At present, the active ingredients for inhibiting the multi-drug resistant escherichia coli need to be found, and a practical basis is provided for developing a novel antibiotic substitute and solving the multi-drug resistant predicament of the drug resistant escherichia coli.
Disclosure of Invention
Aiming at the clinical drug resistance problem stated above, the invention aims to excavate a potential drug-resistant strain inhibitor from the existing medicinal plant resource library, provide the application of deoxyschizandrin in inhibiting the growth of multi-drug-resistant escherichia coli, and provide a practical basis for developing a novel antibiotic substitute and solving the multi-drug resistance dilemma of the drug-resistant escherichia coli.
In order to achieve the purpose, the invention adopts the technical scheme that:
application of deoxyschizandrin in inhibiting growth of multiple drug-resistant Escherichia coli is provided.
Preferably, the drug-resistant escherichia coli is human-derived escherichia coli resistant to ampicillin, nalidixic acid, cefotaxime, ciprofloxacin and cefoxitin. The drug resistance of the escherichia coli is determined by a paper diffusion method, and the antibiotics are selected from a plurality of ampicillin, imipenem, nalidixic acid, ciprofloxacin, cefotaxime, azithromycin, gentamicin, ceftazidime, amikacin and cefoxitin.
Preferably, the minimum bactericidal concentration of the deoxyschizandrin is 25.57 mu g/mL, and the minimum bacteriostatic concentration is 3.13 mu g/mL.
The invention has the beneficial effects that:
based on the research on the effect of deoxyschizandrin on human-derived multi-drug-resistant escherichia coli, the growth of the multi-drug-resistant escherichia coli is inhibited by using the deoxyschizandrin, a new thought is provided for inhibiting the multi-drug-resistant escherichia coli, the deoxyschizandrin has important practical significance, and the deoxyschizandrin has wide application value in the fields of food, medicines and the like.
The invention defines the inhibition effect of the deoxyschizandrin on the drug resistance of the human escherichia coli with antibiotics such as ampicillin, nalidixic acid, cefotaxime, ciprofloxacin and cefoxitin, effectively relieves or solves the problem of drug resistance infection of multiple drug resistance escherichia coli, and reduces the fatality rate.
Detailed Description
The present invention will be described in further detail with reference to examples. The examples are only for the purpose of illustrating the invention and are not to be construed as limiting the invention.
1. Drug sensitivity test of human pathogenic escherichia coli
The invention takes 10 strains of human escherichia coli as starting strains, and selects 10 types of common antibiotic drug sensitive test paper sheets of ampicillin, imipenem, nalidixic acid, ciprofloxacin, cefotaxime, azithromycin, gentamicin, ceftazidime, amikacin and cefoxitin for drug sensitive test.
And (3) selecting and culturing the pure colonies for 18-24 hours, uniformly dissolving the pure colonies in 2-5 mL of sterile physiological saline, and adjusting the turbidity of the pure colonies to be equal to that of a 0.5 McLeod turbiditube. And (4) aseptically sucking 50-200 mu L of bacterial liquid, uniformly coating the bacterial liquid on a flat plate, and standing at room temperature for 3-5 min. The drug sensitive paper pieces (diameter is 6mm) are tightly attached to the surface of the culture medium according to the requirement by using sterile forceps, and three drug sensitive paper pieces of each type are parallel. And placing the inoculated flat plate at 36-37 ℃ for incubation for 16-24 h. The diameter of the bacteriostatic circle is measured by a vernier caliper with the precision of 0.02mm, the sensitivity of the medicine is judged according to the diameter of the bacteriostatic circle, the bacteriostatic result is judged according to the national standard administration committee of the clinical laboratory (CLSl2016), and the judgment standard is shown in Table 1. The experimental results are shown in table 2, and the results show that 8# human escherichia coli can tolerate 5 clinically common antibiotics, so that the escherichia coli is taken as a research object of the next experiment.
TABLE 1 results of the national Committee for standardization management of the clinical laboratory (CLSl2017) standards
TABLE 2 diameter results of zone of inhibition in drug susceptibility test of human pathogenic E.coli
Note: in table 2, the unit of the diameter of the zone of inhibition is mm, and the values are the average values of three replicates.
2. Inhibition effect of deoxyschizandrin on multiple drug-resistant strains
In order to fully consider the medication safety, the invention takes single active ingredient of deoxyschizandrin as a research object and takes imipenem as a positive control to research the drug resistance inhibition effect. Selecting and culturing the pure bacterial colonies for 18-24 h, uniformly dissolving the pure bacterial colonies in 2-5 mL LB liquid medium, adjusting the turbidity of the pure bacterial colonies to be equal to that of a 0.5 McLeod turbiditube, and measuring the OD of the pure bacterial colonies by using an enzyme-labeling instrument600The value is obtained. The schizandrin A with the concentration of 100 mug/mL is prepared by 70-80% ethanol, the liquid medicine, the bacterial liquid and the LB liquid culture medium are added into a 96-hole culture plate for overnight culture by using a test tube double dilution method, and the liquid medicine groups with different concentrations are all three parallel, so that the reliability of experimental data is ensured.
And (3) determining the Minimum Inhibitory Concentration (MIC) of the deoxyschizandrin to the multi-drug-resistant escherichia coli by using a microplate reader. And placing the culture solution with the MIC concentration in a sterile LB liquid culture medium for continuous culture, and determining the Minimum Bactericidal Concentration (MBC) of the deoxyschizandrin to the multi-drug resistant escherichia coli by using a microplate reader, wherein the experimental results are shown in Table 3.
TABLE 3 inhibition results of deoxyschizandrin and imipenem against human-derived multidrug-resistant Escherichia coli
As can be seen from Table 3, schizandrin A has a good inhibitory effect on multi-drug-resistant Escherichia coli resistant to ampicillin, nalidixic acid, cefotaxime, ciprofloxacin and cefoxitin antibiotics, and the MIC and MBC thereof are respectively 25.57 mu g/mL and 3.13 mu g/mL, respectively.
By combining the characteristic of solving the drug resistance of drug-resistant pathogenic bacteria by Chinese herbal medicines and considering the advantages of traditional Chinese medicine resources in Qinba mountainous areas, the drug-resistant infection problem of multi-drug-resistant escherichia coli can be effectively relieved or solved by obtaining the active single-product component deoxyschizandrin and directly combining with the inhibition of clinically main multi-drug-resistant escherichia coli, and the fatality rate is reduced.
In a word, according to the experimental results, the invention provides a new idea for inhibiting the human-derived multi-drug-resistant escherichia coli, and has important practical significance.
Claims (7)
1. The application of deoxyschizandrin in preparing the medicine for inhibiting the growth of multidrug-resistant escherichia coli is characterized in that: the antibiotics which are tolerated by the multi-drug-resistant escherichia coli are ampicillin, nalidixic acid, cefotaxime, ciprofloxacin and cefoxitin.
2. Use according to claim 1, characterized in that: the multi-drug-resistant escherichia coli is human escherichia coli.
3. Use according to claim 1, characterized in that: the resistance of the E.coli was determined by a paper diffusion method.
4. Use according to claim 1, characterized in that: the minimum bactericidal concentration of the deoxyschizandrin to the humanized escherichia coli is 25.57 mug/mL, and the minimum bacteriostatic concentration is 3.13 mug/mL.
5. Use according to claim 1, characterized in that: the deoxyschizandrin has an in-vitro killing effect on the multi-drug-resistant escherichia coli and can inhibit the in-vitro growth of the multi-drug-resistant escherichia coli.
6. The application of deoxyschizandrin in preparing the medicine for resisting multiple drug-resistant escherichia coli is characterized in that: the antibiotics which are tolerated by the multi-drug-resistant escherichia coli are ampicillin, nalidixic acid, cefotaxime, ciprofloxacin and cefoxitin.
7. Use according to claim 6, characterized in that: the multi-drug-resistant escherichia coli is human escherichia coli.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810157681.0A CN108113980B (en) | 2018-02-24 | 2018-02-24 | Application of deoxyschizandrin in inhibiting growth of multi-drug-resistant escherichia coli |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810157681.0A CN108113980B (en) | 2018-02-24 | 2018-02-24 | Application of deoxyschizandrin in inhibiting growth of multi-drug-resistant escherichia coli |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108113980A CN108113980A (en) | 2018-06-05 |
| CN108113980B true CN108113980B (en) | 2020-03-03 |
Family
ID=62234495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810157681.0A Active CN108113980B (en) | 2018-02-24 | 2018-02-24 | Application of deoxyschizandrin in inhibiting growth of multi-drug-resistant escherichia coli |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108113980B (en) |
-
2018
- 2018-02-24 CN CN201810157681.0A patent/CN108113980B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108113980A (en) | 2018-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104490749B (en) | Radix Glycyrrhizae liquid fermentate, cosmetics containing fermentation material and its preparation method and application | |
| CN110251526A (en) | Paeoniflorin is inhibiting the application in the growth of Carbapenem-resistant parapneumonia klebsiella | |
| US11654174B2 (en) | Method of chinese herbal medicine extract used for treating multiple diseases caused by drug resistant bacteria infection | |
| CN102920771B (en) | Medicine for treating poultry coccidiosis | |
| CN101543499B (en) | Application of natural compound ursolic acid on antibiosis | |
| CN101829130A (en) | Compound resveratrol anti-inflammatory and itching relieving medicament combination and purpose thereof | |
| CN108113980B (en) | Application of deoxyschizandrin in inhibiting growth of multi-drug-resistant escherichia coli | |
| CN110279679B (en) | Application of citral in inhibition of growth of multiple drug-resistant enterobacter cloacae | |
| CN105920082B (en) | Application of pithecellobium clypearia extract in preparation of medicine for resisting generation of extended-spectrum β -lactamase Klebsiella pneumoniae | |
| CN111939156A (en) | Combined antibacterial pharmaceutical composition and application thereof | |
| CN109646447B (en) | Application of rhizoma paridis saponin in resisting malassezia furfur and candida albicans products | |
| CN110279701A (en) | Ursolic acid is inhibiting the application in the growth of multidrug resistant enterobacter cloacae | |
| CN110215445B (en) | Application of vanillic acid in inhibiting growth of multiple drug-resistant enterobacter hopcalis | |
| Huamaní et al. | Comparison of the antifungal efficacy of four concentrations of Minthostachys mollis (muña) essential oil against Candida albicans: An In Vitro Study | |
| CN110876749B (en) | Application of chelerythrine in inhibiting growth of multi-drug resistant serratia marcescens | |
| CN110946862B (en) | Application of sanguinarine in inhibition of growth of multiple drug-resistant enterobacter hopcalis | |
| CN110960545A (en) | Application of punicalagin in inhibiting growth of multidrug-resistant klebsiella pneumoniae | |
| CN112353877A (en) | Application of valerian total alkaloid extract in preparation of malassezia inhibitor | |
| CN110507653A (en) | Domperidone and its with taxol combination preparation treating cancer drug in application | |
| Rao et al. | Antibacterial activity of different crude extracts of Dodonaea viscosa | |
| CN110934871B (en) | Application of sanguinarine in inhibiting growth of multiple drug-resistant serratia marcescens | |
| CN105663100B (en) | The purposes of drug fingomode | |
| Ruanguan et al. | Antibiotic therapy for typhoid fever | |
| CN111228280A (en) | Application of pulsatilla saponin A3 in inhibition of growth of multidrug-resistant providencia rettgeri | |
| CN110623963B (en) | Pharmaceutical composition for treating ovarian cancer and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |